UAB 0718 - Phase II Trial to Assess Target Oral Therapy as Adjuvant Chemoprevention in High-Risk Head and Neck Cancer

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
University of Alabama at Birmingham
Study ID
NCT00570232
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • Erlotinib — DRUG
    150 mg per day by mouth for 12 months

Study Details

The purpose of this study is to determine whether erlotinib will be effective in controlling cancer that has returned after treatment with salvage surgery and radiation. This study will also determine what effects, good and/or bad, this drug has on the participants.

Key Dates

First listed
Dec 10, 2007
Start date
Dec 31, 2007
Status verified
May 2015
Primary completion
Dec 31, 2014
Completion
Mar 31, 2015

Study Design

Enrollment
31 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION

Arms

  • Other: Tarceva
    All patients will be prescribed erlotinib 150mg daily

Primary Outcome Measure

Number of Participants Demonstrating the Safety and Tolerability of Long Term Erlotinib Treatment [ Time Frame: 12 - 24 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of Alabama at BirminghamBirminghamAlabama35233-

Find similar trials in Birmingham, AL

By condition
Head and neck cancer
By specialty
OncologyENT
By research site
University of Alabama at Birmingham· Birmingham, AL

Related Studies